Searchable abstracts of presentations at key conferences in endocrinology

ea0090p422 | Pituitary and Neuroendocrinology | ECE2023

Effects of a GLP-1 agonist on consumption of alcohol in patients treated for smoking cessation

Sofia Probst Leila , Monnerat Sophie , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Bathelt Cemile , Christ-Crain Mirjam , Winzeler Bettina

Introduction: Alcohol use disorder AUD causes high socio-economic costs and has a detrimental impact on health globally, being considered a key risk factor for non-communicable diseases. In Switzerland, four substances are currently approved for treatment of AUD, with varying effects. Taking into consideration the complex nature of the disease and the heterogeneity of affect patients, it becomes evident that there is need for new treatment targets. A body of preclinical studie...

ea0090p69 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Effects of Glucagon-Like Peptide-1 Analogs on Sexual Desire: A randomized, double-blind, placebo-controlled crossover trial

Lengsfeld Sophia , Hasenbohler Flavia , Probst Leila , Baur Fabienne , Emara Yara , Bathelt Cemile , Werlen Laura , Vogt Deborah , Caviezel Brida , Vukajlovic Tanja , Christ-Crain Mirjam , Winzeler Bettina

Background: GLP-1 analogs are prescribed for diabetes and obesity due to their well-known insulinotropic, satiation-promoting and appetite-suppressant effects. Several studies also investigated the effects of GLP-1 analogs on reward to addictive drugs such as alcohol, nicotine and cocaine. Pre-clinical studies suggest that sexual desire, as another type of natural reward, could also be affected by GLP-1 analogs. Since sexuality is a very important aspect of human wellbeing and...